Rick Harrison of Television's "Pawn Stars" Discusses His Revelations on Seeking Treatment for His Very High Triglycerides in National Awareness Campaign
Harrison Helps Educate on Differences Between Dietary Fish Oil Supplements and Prescription EPA-only Omega-3 Therapy
June 25, 2014 --
NEW YORK, June 25, 2014 /PRNewswire/ --Amarin Corporation, plc (Nasdaq: AMRN), today announced a national partnership with Rick Harrison, star of the hit television show "Pawn Stars," in launching Lower My Trigs, a national awareness campaign about seeking treatment for very high triglycerides (VHTG) (> 500 mg/dL), a problem faced by up to four million Americans. Amarin has engaged Harrison as a spokesperson for the campaign to inform patients and family members, their physicians and other health care professionals about the health risks of very high triglycerides and the importance of patients discussing available treatment options with their physician.
Rick Harrison, known for his keen assessment of the value of rare and unique items from 16th century manuscripts to Elvis memorabilia shares his journey from diagnosis to treatment, including his road to learning more about treatment myths and physician-supervised options. Rick provides his story in a video at www.lowermytrigs.com.
"A pawn store's success is based on finding out the real story about any item before making a decision to lower my risk. When it comes to my own health, I apply that same wisdom. So, I did my research, and was surprised to learn that there are hundreds of dietary fish oil supplements and most of these products contain DHA which can actually raise bad cholesterol in patients like me," shared Rick Harrison. "I realized that I needed to work with a doctor who understood the differences."
Rick's physician recommended that he exercise, diet and take Vascepa (icosapent ethyl) capsules. Vascepa is available by prescription only and there is no other product available that contains only the omega-3 fatty acid, EPA. EPA-only Vascepa is also the only omega-3 prescription product approved for use by the FDA in adult patients with triglyceride levels of at least 500 mg/dL that is not associated with increases in bad cholesterol.
"As a patient with very high triglycerides, Rick has applied the same level of energy and dedication toward improving his health as he does to making the right decisions for his business. As a result, he and his doctor have agreed on EPA-only Vascepa as the appropriate choice for Rick to treat his very high triglyceride levels," said John Thero, President and Chief Executive Officer of Amarin. "By partnering with Rick on the Lower My Trigs campaign, it is our hope to greatly increase awareness of very high triglyceride levels and the importance of seeking a doctor's guidance to control this condition. We hope that the millions of other patients with very high triglycerides will learn more about their condition and actively participate in their successful treatment."
In addition to patient and physician resources, visitors to www.lowermytrigs.com can also save on Vascepa, the treatment Rick's physician prescribed, with a Vascepa Savings Card, if eligible.
About Vascepa(icosapent ethyl) capsules
Vascepa(icosapent ethyl) capsules, known in scientific literature as AMR101, is a highly pure-EPAomega-3 prescription product in a 1 gram capsule.
Indications and Usage
- Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (> 500 mg/dL) hypertriglyceridemia.
- The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.
Important Safety Information for Vascepa
- Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components and should be used with caution in patients with known hypersensitivity to fish and/or shellfish.
- The most common reported adverse reaction (incidence > 2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo).
FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND ATWWW.VASCEPA.COM.
Vascepa has been approved for use by theFDAas an adjunct to diet to reduce triglyceride levels in adult patients with severe (> 500 mg/dL) hypertriglyceridemia.Vascepa is under various stages of development for potential use in other indications that have not been approved by the FDA.Nothing in this press release should be construed as marketing the use of Vascepa in any indication that has not been approved by theFDA.
Amarin Corporation plcis a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.Amarin'sproduct development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa(icosapent ethyl),Amarin'sfirstFDAapproved product, is an ultra-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
This press release contains forward-looking statements, including statements about the potential efficacy, safety and therapeutic benefits of Amarin's product, Amarin's clinical trial results, including statements about the clinical importance of certain parameters and the impact of Vascepa on such parameters. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, including the risk that historical clinical trial results may not be predictive of future results in replicated in larger patient populations and that studied lipid parameters may not have clinically meaningful effect or support regulatory approvals. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Availability of other information about Amarin
Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations website (http://www.amarincorp.com/investor-splash.html), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
PAWN STARS is a trademark of A&E Television Networks, LLC. The Amarin group of companies is not affiliated or associated with A&E Television Networks, LLC.
Amarin contact information
Investor Relations and Corporate Communications
Amarin Corporation plc